Published in J Clin Invest on April 01, 2010
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy (2016) 7.05
A comprehensive glossary of autophagy-related molecules and processes (2nd edition). Autophagy (2011) 2.02
Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood (2011) 1.91
Autophagy and apoptosis: what is the connection? Trends Cell Biol (2011) 1.81
Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med (2012) 1.68
Autophagy: for better or for worse. Cell Res (2011) 1.65
Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nat Genet (2015) 1.52
Autosis and autophagic cell death: the dark side of autophagy. Cell Death Differ (2014) 1.49
Obatoclax (GX15-070) triggers necroptosis by promoting the assembly of the necrosome on autophagosomal membranes. Cell Death Differ (2013) 1.42
Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. Oncotarget (2012) 1.34
Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia. Leukemia (2012) 1.34
Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK. Cell Death Dis (2010) 1.23
Mitophagy-dependent necroptosis contributes to the pathogenesis of COPD. J Clin Invest (2014) 1.23
GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy. Cell Death Dis (2010) 1.17
zVAD-induced autophagic cell death requires c-Src-dependent ERK and JNK activation and reactive oxygen species generation. Autophagy (2011) 1.14
Human cancer growth and therapy in immunodeficient mouse models. Cold Spring Harb Protoc (2014) 1.12
Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling. Blood (2011) 1.12
Cell death by autophagy: emerging molecular mechanisms and implications for cancer therapy. Oncogene (2015) 1.11
Staurosporine induces necroptotic cell death under caspase-compromised conditions in U937 cells. PLoS One (2012) 1.11
Mcl-1 ubiquitination: unique regulation of an essential survival protein. Cells (2014) 1.09
Smac mimetic bypasses apoptosis resistance in FADD- or caspase-8-deficient cells by priming for tumor necrosis factor α-induced necroptosis. Neoplasia (2011) 1.08
A JNK-mediated autophagy pathway that triggers c-IAP degradation and necroptosis for anticancer chemotherapy. Oncogene (2013) 1.06
Glucocorticoid dose determines osteocyte cell fate. FASEB J (2011) 1.06
Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review. Expert Opin Ther Pat (2011) 1.04
Attenuation of TNFSF10/TRAIL-induced apoptosis by an autophagic survival pathway involving TRAF2- and RIPK1/RIP1-mediated MAPK8/JNK activation. Autophagy (2012) 1.04
Autophagy in the physiology and pathology of the central nervous system. Cell Death Differ (2014) 1.04
Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia. Blood (2013) 0.99
A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis. Blood (2014) 0.97
The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia. Haematologica (2010) 0.97
Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors. Cell Death Dis (2012) 0.94
The mechanism of necroptosis in normal and cancer cells. Cancer Biol Ther (2013) 0.93
Shikonin kills glioma cells through necroptosis mediated by RIP-1. PLoS One (2013) 0.93
An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies. Core Evid (2013) 0.91
Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts. Clin Cancer Res (2014) 0.91
Photoreceptor cell death and rescue in retinal detachment and degenerations. Prog Retin Eye Res (2013) 0.91
The synergism of MCL1 and glycolysis on pediatric acute lymphoblastic leukemia cell survival and prednisolone resistance. Haematologica (2013) 0.90
Differential roles of RIPK1 and RIPK3 in TNF-induced necroptosis and chemotherapeutic agent-induced cell death. Cell Death Dis (2015) 0.89
Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies? Cell Death Dis (2014) 0.89
Inhibiting autophagy potentiates the anticancer activity of IFN1@/IFNα in chronic myeloid leukemia cells. Autophagy (2012) 0.89
RFX1-dependent activation of SHP-1 induces autophagy by a novel obatoclax derivative in hepatocellular carcinoma cells. Oncotarget (2014) 0.89
BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells. Cell Death Dis (2013) 0.88
Autophagy in acute kidney injury. Kidney Int (2016) 0.88
Targeting SQSTM1/p62 induces cargo loading failure and converts autophagy to apoptosis via NBK/Bik. Mol Cell Biol (2014) 0.88
WISP1: Clinical insights for a proliferative and restorative member of the CCN family. Curr Neurovasc Res (2014) 0.88
Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer. Neoplasia (2011) 0.87
Potent antitumor activity of oncolytic adenovirus expressing Beclin-1 via induction of autophagic cell death in leukemia. Oncotarget (2013) 0.86
Interferon regulatory factor-1 signaling regulates the switch between autophagy and apoptosis to determine breast cancer cell fate. Cancer Res (2015) 0.86
Cutting through the complexities of mTOR for the treatment of stroke. Curr Neurovasc Res (2014) 0.86
The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas. Adv Hematol (2011) 0.85
Targeting the apoptosis pathway in hematologic malignancies. Leuk Lymphoma (2014) 0.85
Image-based RNA interference screening reveals an individual dependence of acute lymphoblastic leukemia on stromal cysteine support. Oncotarget (2014) 0.84
Necroptosis Is an Important Severity Determinant and Potential Therapeutic Target in Experimental Severe Pancreatitis. Cell Mol Gastroenterol Hepatol (2016) 0.84
CYLD Regulates Noscapine Activity in Acute Lymphoblastic Leukemia via a Microtubule-Dependent Mechanism. Theranostics (2015) 0.83
Targeting mTOR/p70S6K/glycolysis signaling pathway restores glucocorticoid sensitivity to 4E-BP1 null Burkitt Lymphoma. BMC Cancer (2015) 0.82
Glucocorticoids and osteocyte autophagy. Bone (2013) 0.82
Identification of novel predictor classifiers for inflammatory bowel disease by gene expression profiling. PLoS One (2013) 0.82
Necroptosis: an alternative cell death program defending against cancer. Biochim Biophys Acta (2016) 0.82
Tissue acidosis induces neuronal necroptosis via ASIC1a channel independent of its ionic conduction. Elife (2015) 0.82
Taking aim at Alzheimer's disease through the mammalian target of rapamycin. Ann Med (2014) 0.82
Cancer therapy in the necroptosis era. Cell Death Differ (2016) 0.81
Assessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics. Oncotarget (2014) 0.81
Cell death induction by the BH3 mimetic GX15-070 in thyroid carcinoma cells. J Exp Clin Cancer Res (2015) 0.80
Aging and uremia: Is there cellular and molecular crossover? World J Nephrol (2015) 0.80
MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies. ISRN Hematol (2013) 0.80
Protective Macroautophagy Is Involved in Vitamin E Succinate Effects on Human Gastric Carcinoma Cell Line SGC-7901 by Inhibiting mTOR Axis Phosphorylation. PLoS One (2015) 0.79
Placental autophagy regulation by the BOK-MCL1 rheostat. Autophagy (2013) 0.79
Pan-Bcl-2 inhibitor Obatoclax is a potent late stage autophagy inhibitor in colorectal cancer cells independent of canonical autophagy signaling. BMC Cancer (2015) 0.79
Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma. Oncotarget (2016) 0.78
Necroptosis in tumorigenesis, activation of anti-tumor immunity, and cancer therapy. Oncotarget (2016) 0.78
The BH3 Mimetic Obatoclax Accumulates in Lysosomes and Causes Their Alkalinization. PLoS One (2016) 0.78
5-Aminolevulinic Acid-Mediated Sonodynamic Therapy Inhibits RIPK1/RIPK3-Dependent Necroptosis in THP-1-Derived Foam Cells. Sci Rep (2016) 0.78
Relevance of necroptosis in cancer. Immunol Cell Biol (2016) 0.78
Wogonin induces Beclin-1/PI3K and reactive oxygen species-mediated autophagy in human pancreatic cancer cells. Oncol Lett (2016) 0.78
Autophagy collaborates with ubiquitination to downregulate oncoprotein E2A/Pbx1 in B-cell acute lymphoblastic leukemia. Blood Cancer J (2015) 0.76
BCL2 Inhibitor (ABT-737): A Restorer of Prednisolone Sensitivity in Early T-Cell Precursor-Acute Lymphoblastic Leukemia with High MEF2C Expression? PLoS One (2015) 0.76
Matrine induces RIP3-dependent necroptosis in cholangiocarcinoma cells. Cell Death Discov (2017) 0.75
The autophagy-lysosomal system in subarachnoid haemorrhage. J Cell Mol Med (2016) 0.75
Inhibition of regulated cell death by cell-penetrating peptides. Cell Mol Life Sci (2016) 0.75
Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid Cancer. Theranostics (2017) 0.75
Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood (2017) 0.75
MEK Inhibition Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia (B-ALL) Cells to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy. PLoS One (2016) 0.75
Natural Compounds As Modulators of Non-apoptotic Cell Death in Cancer Cells. Curr Genomics (2017) 0.75
Comparison of in vitro antileukemic activity of obatoclax and ABT-737. Tumour Biol (2016) 0.75
Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia. Leukemia (2017) 0.75
Relationship between triterpenoid anticancer drug resistance, autophagy, and caspase-1 in adult T-cell leukemia. PeerJ (2016) 0.75
Effects of a novel β-lapachone derivative on Trypanosoma cruzi: Parasite death involving apoptosis, autophagy and necrosis. Int J Parasitol Drugs Drug Resist (2016) 0.75
Therapeutic Implications of Autophagy Inducers in Immunological Disorders, Infection, and Cancer. Int J Mol Sci (2017) 0.75
MYC is a positive regulator of choline metabolism and impedes mitophagy-dependent necroptosis in diffuse large B-cell lymphoma. Blood Cancer J (2017) 0.75
Autophagy in Cancer Therapy. Front Oncol (2017) 0.75
BH3 mimetic Obatoclax (GX15-070) mediates mitochondrial stress predominantly via MCL-1 inhibition and induces autophagy-dependent necroptosis in human oral cancer cells. Oncotarget (2016) 0.75
Autophagy is required for cell survival under L-asparaginase-induced metabolic stress in acute lymphoblastic leukemia cells. Oncogene (2017) 0.75
The mechanisms of graphene-based materials-induced programmed cell death: a review of apoptosis, autophagy, and programmed necrosis. Int J Nanomedicine (2017) 0.75
Autophagy in the pathogenesis of disease. Cell (2008) 34.68
An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature (2005) 22.40
Defining the role of mTOR in cancer. Cancer Cell (2007) 21.63
Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell (2005) 21.01
Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest (2003) 16.67
Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci U S A (2003) 15.59
Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell (2005) 13.59
Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. EMBO J (2007) 11.72
Growing roles for the mTOR pathway. Curr Opin Cell Biol (2005) 11.66
Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol (2005) 11.63
Treatment of acute lymphoblastic leukemia. N Engl J Med (2006) 11.30
Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8. Science (2004) 10.77
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell (2006) 10.29
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell (2006) 10.19
Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol (2005) 9.76
Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol (2008) 9.24
The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol Cell (2000) 8.95
Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat Cell Biol (2004) 8.85
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell (2006) 8.59
Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol (2000) 8.49
Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell (2008) 7.61
Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell (2006) 7.18
Autophagic cell death: the story of a misnomer. Nat Rev Mol Cell Biol (2008) 6.78
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A (2007) 4.92
Growth arrest and autophagy are required for salivary gland cell degradation in Drosophila. Cell (2007) 4.55
BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell (2007) 4.55
RIP mediates tumor necrosis factor receptor 1 activation of NF-kappaB but not Fas/APO-1-initiated apoptosis. EMBO J (1996) 4.33
Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci U S A (2004) 4.20
Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med (2004) 4.16
Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell (2006) 3.93
Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J Clin Invest (2009) 3.23
RIP kinases at the crossroads of cell death and survival. Cell (2009) 3.04
Necroptosis: a specialized pathway of programmed necrosis. Cell (2008) 2.61
Inhibition of autophagy prevents hippocampal pyramidal neuron death after hypoxic-ischemic injury. Am J Pathol (2008) 2.57
FADD and caspase-8 control the outcome of autophagic signaling in proliferating T cells. Proc Natl Acad Sci U S A (2008) 2.52
Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. PLoS One (2009) 2.20
Autophagy, not apoptosis, is essential for midgut cell death in Drosophila. Curr Biol (2009) 2.20
Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood (2008) 2.18
Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res (2008) 2.17
Ubiquitination of RIP1 regulates an NF-kappaB-independent cell-death switch in TNF signaling. Curr Biol (2007) 2.15
The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood (2007) 2.14
Regulation of early wave of germ cell apoptosis and spermatogenesis by deubiquitinating enzyme CYLD. Dev Cell (2007) 2.05
Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest (2007) 2.05
Dexamethasone represses signaling through the mammalian target of rapamycin in muscle cells by enhancing expression of REDD1. J Biol Chem (2006) 1.78
A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res (2008) 1.77
Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy. Cell Death Differ (2009) 1.67
The tyrosine kinase Lck is a positive regulator of the mitochondrial apoptosis pathway by controlling Bak expression. Oncogene (2006) 1.65
Dexamethasone-induced gene 2 (dig2) is a novel pro-survival stress gene induced rapidly by diverse apoptotic signals. J Biol Chem (2003) 1.47
Atg5 and Bcl-2 provide novel insights into the interplay between apoptosis and autophagy. Cell Death Differ (2007) 1.41
Divergent mechanisms of glucocorticoid resistance in experimental models of pediatric acute lymphoblastic leukemia. Cancer Res (2007) 1.40
Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. Blood (2008) 1.36
Apaf-1 and caspase-9 deficiency prevents apoptosis in a Bax-controlled pathway and promotes clonogenic survival during paclitaxel treatment. Blood (2007) 1.12
Glucocorticoid-induced glucocorticoid-receptor expression and promoter usage is not linked to glucocorticoid resistance in childhood ALL. Blood (2006) 1.05
Evolution of BFM trials for childhood ALL. Ann Hematol (2004) 0.93
Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway. Blood (2007) 0.92
Regulation of annexin II by cytokine-initiated signaling pathways and E2A-HLF oncoprotein. Blood (2003) 0.89
Methods to analyze cellular necroptosis. Methods Mol Biol (2009) 0.79
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet (2007) 3.94
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet (2008) 3.69
S100 proteins: structure, functions and pathology. Front Biosci (2002) 3.28
BLUEPRINT to decode the epigenetic signature written in blood. Nat Biotechnol (2012) 3.24
In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell (2008) 2.78
Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol (2005) 2.75
Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias. J Exp Med (2011) 2.59
Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol (2010) 2.53
Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa. Science (2010) 2.49
Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat Genet (2010) 2.47
Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet (2002) 2.46
Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87. J Clin Oncol (2005) 2.36
Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. Blood (2007) 2.31
Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol (2012) 2.29
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood (2011) 2.18
Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol (2003) 2.12
An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice. Nat Med (2008) 2.12
Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood (2006) 2.10
Do lower cuff pressures reduce damage to the tracheal mucosa? A scanning electron microscopy study in neonatal pigs. Paediatr Anaesth (2012) 2.05
Osteonecrosis: a treatment related toxicity in childhood acute lymphoblastic leukemia (ALL)--experiences from trial ALL-BFM 95. Pediatr Blood Cancer (2005) 2.02
IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood (2013) 1.91
Predicting adverse events in children with fever and chemotherapy-induced neutropenia: the prospective multicenter SPOG 2003 FN study. J Clin Oncol (2010) 1.81
Rapid dephosphorylation of the renal sodium chloride cotransporter in response to oral potassium intake in mice. Kidney Int (2013) 1.80
Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol (2010) 1.79
Subcellular targeting of metabolic enzymes to titin in heart muscle may be mediated by DRAL/FHL-2. J Cell Sci (2002) 1.77
First-day step-down to oral outpatient treatment versus continued standard treatment in children with cancer and low-risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study. Pediatr Blood Cancer (2012) 1.74
Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA (2005) 1.74
The transcriptional activator PAX3-FKHR rescues the defects of Pax3 mutant mice but induces a myogenic gain-of-function phenotype with ligand-independent activation of Met signaling in vivo. Genes Dev (2003) 1.73
L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer (2010) 1.69
Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. Cancer Res (2004) 1.67
NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD(+)-sirtuin-1-dependent pathway. Nat Med (2009) 1.66
Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood. Blood (2009) 1.64
Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol (2004) 1.64
Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol (2010) 1.62
Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002. J Clin Oncol (2013) 1.62
Varicella vaccination in a child with acute lymphoblastic leukaemia. Lancet (2007) 1.61
Activating mutations in human acute megakaryoblastic leukemia. Blood (2008) 1.56
Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood (2007) 1.56
Leukemic stem cells in childhood high-risk ALL/t(9;22) and t(4;11) are present in primitive lymphoid-restricted CD34+CD19- cells. Cancer Res (2005) 1.55
LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia. Nat Med (2006) 1.52
IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica (2012) 1.50
Real-time quantitative broad-range PCR assay for detection of the 16S rRNA gene followed by sequencing for species identification. J Clin Microbiol (2006) 1.49
Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol (2010) 1.47
SKY reveals a high frequency of unbalanced translocations involving chromosome 6 in t(12;21)-positive acute lymphoblastic leukemia. Leuk Res (2007) 1.46
Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. Blood (2002) 1.45
Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype. Blood (2013) 1.45
The calcium-binding protein S100A2 interacts with p53 and modulates its transcriptional activity. J Biol Chem (2005) 1.44
CNS irradiation in pediatric acute myleoid leukemia: equal results by 12 or 18 Gy in studies AML-BFM98 and 2004. Pediatr Blood Cancer (2011) 1.44
The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model. J Clin Invest (2009) 1.44
Treatment of childhood acute lymphoblastic leukemia. Semin Hematol (2009) 1.42
Health-related quality of life in children with newly diagnosed cancer: a one year follow-up study. Health Qual Life Outcomes (2006) 1.42
Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. Blood (2004) 1.39
Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? J Clin Oncol (2004) 1.39
Deficiency of the adaptor SLP-65 in pre-B-cell acute lymphoblastic leukaemia. Nature (2003) 1.39
Herpes simplex virus 1 envelopment follows two diverse pathways. J Virol (2005) 1.37
The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol (2005) 1.37
Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia. Blood (2003) 1.36
Childhood and adolescent lymphoid and myeloid leukemia. Hematology Am Soc Hematol Educ Program (2004) 1.35
Cloning of genes involved in chromosomal translocations by high-resolution single nucleotide polymorphism genomic microarray. Proc Natl Acad Sci U S A (2008) 1.34
Impairment of nuclear pores in bovine herpesvirus 1-infected MDBK cells. J Virol (2005) 1.25
Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. J Clin Oncol (2006) 1.25